Pharmacokinetics of recombinant factor XIII at steady state in patients with congenital factor XIII A-subunit deficiency

Journal of Thrombosis and Haemostasis

Volumn 12, Issue 12, 2014, Pages 2038-2043

  Kerlin, B ^a   Brand, B ^b   Inbal, A ^c   Halimeh, S ^d   Nugent, D ^e   Lundblad, M ^f   Tehranchi, R ^f  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c TEL AVIV UNIVERSITY   (Israel)

^d Medical Thrombosis and Haemophilia Treatment Center   (Germany)

^e CHILDREN S HOSPITAL OF ORANGE COUNTY   (United States)

^f NOVO NORDISK A S   (Denmark)

Author keywords

Factor XIII; Factor XIII deficiency; Fibrinolysis; Pharmacokinetics; Recombinant factor XIII A2

Indexed keywords

CATRIDECACOG; ANTIBODY; BLOOD CLOTTING FACTOR 13A; RECOMBINANT PROTEIN;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD CLOTTING FACTOR 13 DEFICIENCY; BLOOD VOLUME; CHILD; CLINICAL TRIAL; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; FEMALE; HUMAN; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; PROPHYLAXIS; STEADY STATE; VOLUME OF DISTRIBUTION AT STEADY-STATE; AGED; BLOOD; CHEMISTRY; COHORT ANALYSIS; DRUG ADMINISTRATION; FACTOR XIII DEFICIENCY; MIDDLE AGED; MULTICENTER STUDY; PATIENT SAFETY; TIME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIBODIES; AREA UNDER CURVE; CHILD; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; FACTOR XIII DEFICIENCY; FACTOR XIIIA; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT SAFETY; RECOMBINANT PROTEINS; TIME FACTORS; YOUNG ADULT;

EID: 84916631979     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12739     Document Type: Article

References (29)

1. Ichinose A. Factor XIII is a key molecule at the intersection of coagulation and fibrinolysis as well as inflammation and infection control. Int J Hematol 2012; 95: 362-70.
2. Karimi M, Bereczky Z, Cohan N, Muszbek L. Factor XIII deficiency. Semin Thromb Hemost 2009; 35: 426-38.
3. World Federation of Hemophilia. Report on the Annual Global Survey 2011. WFH website. http://www1.wfh.org/publications/files/pdf-1488.pdf. Accessed 19 December 2013.
4. Lusher J, Pipe SW, Alexander S, Nugent D. Prophylactic therapy with Fibrogammin P is associated with a decreased incidence of bleeding episodes: a retrospective study. Haemophilia 2010; 16: 316-21.
5. Brackmann HH, Egbring R, Ferster A, Fondu P, Girardel JM, Kreuz W, Masure R, Miloszewski K, Stibbe J, Zimmermann R, Krzensk U, Hoos A. Pharmacokinetics and tolerability of factor XIII concentrates prepared from human placenta or plasma: a crossover randomised study. Thromb Haemost 1995; 74: 622-5.
6. ® P) for severe congenital factor XIII deficiency: a prospective multicentre study. J Thromb Haemost 2011; 9: 1264-6.
7. United Kingdom Haemophelia Centre Doctors' Organisation. Guidelines on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. Haemophilia 2003; 9: 1-23.
8. National Hemophilia Foundation Medical and Scientific Advisory Council. MASAC recommendations concerning products licensed for the treatment of hemophilia and other bleeding disorders (MASAC Document #225). National Hemophilia Foundation website. http://www.hemophilia.org/Researchers-Healthcare-Providers/Medical-and-Scientific-Advisory-Council-MASAC/All-MASAC-Recommendations/Recommendations-Concerning-Products-Licensed-for-the-Treatment-of-Hemophilia-and-Other-Bleeding-Disorders. Accessed 9 October 2014.
9. Inbal A, Oldenburg J, Carcao M, Rosholm A, Tehranchi R, Nugent D. Recombinant factor XIII: a safe and novel treatment for congenital factor XIII deficiency. Blood 2012; 119: 5111-7.
10. Williams M, Will A, Stenmo C, Rosholm A, Tehranchi R. Pharmacokinetics of recombinant factor XIII in young children with congenital FXIII deficiency and comparison with older patients. Haemophilia 2014; 20: 99-105.
11. Bolton-Maggs PH, Perry DJ, Chalmers EA, Parapia LA, Wilde JT, Williams MD, Collins PW, Kitchen S, Dolan G, Mumford AD. The rare coagulation disorders-review with guidelines for management from the United Kingdom Haemophilia Centre Doctors' Organisation. Haemophilia 2004; 10: 593-628.
12. Gootenberg JE. Factor concentrates for the treatment of factor XIII deficiency. Curr Opin Hematol 1998; 5: 372-5.
13. Hsieh L, Nugent D. Factor XIII deficiency. Haemophilia 2008; 14: 1190-200.
14. Peyvandi F, Cattaneo M, Inbal A, De Moerloose P, Spreafico M. Rare bleeding disorders. Haemophilia 2008; 14(Suppl 3): 202-10.
15. Barnes C. Importance of pharmacokinetics in the management of hemophilia. Pediatr Blood Cancer 2013; 60(Suppl 1): S27-9.
16. Bjorkman S. Limited blood sampling for pharmacokinetic dose tailoring of FVIII in the prophylactic treatment of haemophilia A. Haemophilia 2010; 16: 597-605.
17. Shapiro AD, Korth-Bradley J, Poon MC. Use of pharmacokinetics in the coagulation factor treatment of patients with haemophilia. Haemophilia 2005; 11: 571-82.
18. National Institute for Biological Standards and Control. 1st International Standard Factor XIII plasma. NIBSC code: 02/206. Instructions for use (Version 4.0). WHO International Standard. www.nibsc.org/documents/ifu/02-206.pdf. Accessed 19 December 2013.
19. Lovejoy AE, Reynolds TC, Visich JE, Butine MD, Young G, Belvedere MA, Blain RC, Pederson SM, Ishak LM, Nugent DJ. Safety and pharmacokinetics of recombinant factor XIII-A2 administration in patients with congenital factor XIII deficiency. Blood 2006; 108: 57-62.
20. Reynolds TC, Butine MD, Visich JE, Gunewardena KA, MacMahon M, Pederson S, Bishop PD, Morton KM. Safety, pharmacokinetics, and immunogenicity of single-dose rFXIII administration to healthy volunteers. J Thromb Haemost 2005; 3: 922-8.
21. Visich JE, Zuckerman LA, Butine MD, Gunewardena KA, Wild R, Morton KM, Reynolds TC. Safety and pharmacokinetics of recombinant factor XIII in healthy volunteers: a randomized, placebo-controlled, double-blind, multi-dose study. Thromb Haemost 2005; 94: 802-7.
22. Jennings I, Kitchen S, Woods TA, Preston FE, Uk N. Problems relating to the laboratory diagnosis of factor XIII deficiency: a UK NEQAS study. J Thromb Haemost 2003; 1: 2603-8.
23. Lawrie AS, Green L, Mackie IJ, Liesner R, Machin SJ, Peyvandi F. Factor XIII-an under diagnosed deficiency-are we using the right assays? J Thromb Haemost 2010; 8: 2478-82.
24. Peyvandi F, Di Michele D, Bolton-Maggs PH, Lee CA, Tripodi A, Srivastava A, Project on Consensus Definitions in Rare Bleeeding Disorders of the Factor VII/Factor IX Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. Classification of rare bleeding disorders (RBDs) based on the association between coagulant factor activity and clinical bleeding severity. J Thromb Haemost 2012; 10: 1938-43.
25. Schroeder V, Kohler HP. New developments in the area of factor XIII. J Thromb Haemost 2013; 11: 234-44.
26. Hsu P, Zantek ND, Meijer P, Hayward CP, Brody J, Zhang X, Smock KJ, van Cott EM. Factor XIII assays and associated problems for laboratory diagnosis of factor XIII deficiency: an analysis of international proficiency testing results. Semin Thromb Hemost 2014; 40: 232-8.
27. Kohler HP, Ichinose A, Seitz R, Ariens RA, Muszbek L, on behalf of the Factor XIII and Fibrinogen SSC Subcommittee of The ISTH. Subcommittee of The ISTH. Diagnosis and classification of factor XIII deficiencies. J Thromb Haemost 2011; 9: 1404-6.
28. Meijer P. Clinically needed sensitivity for very low levels of Factor XIII: not yet proven for a new functional assay. Clin Chem Lab Med 2011; 49: 1753-4.
29. Karpati L, Penke B, Katona E, Balogh I, Vamosi G, Muszbek L. A modified, optimized kinetic photometric assay for the determination of blood coagulation factor XIII activity in plasma. Clin Chem 2000; 46: 1946-55.